根据Nektar向美国证券交易委员会提交的文件，加利福尼亚州的一个联邦陪审团裁定，礼来公司必须向Nektar Therapeutics支付9000万美元，因其违反了两家公司共同开发的一款自身免疫候选药物的相关协议。
A federal jury in California has determined that Eli Lilly must pay Nektar Therapeutics $90 million for breaking an agreement related to an autoimmune drug candidate that the companies developed together, according to a Nektar filing with the US Securities and Exchange Commission.